QualityDipStocks / Health Care · Medical instruments
iRadimed IRMD
Outside our quality screen, so we don’t track its dips. It’s 24% below its 52-week high.
Outside our quality screen, trading above our fair value estimate.
Worth knowing
- Down 26% from its 52-week high while revenue grew 11%
From the data on this page, as of the last close. How we pick these
- Fair value est.
- $62.63−21%
- Market Value
- forming
- Off 52-wk high
- −24%
- Risk vs market
- Lowbeta 0.62
52-week range 10% of the way from its 52-week low to its high
Price $79.42Fair value est. $62.63
5 bullish · 3 bearish See why
Repriced or dip?
Dip: business intact
The price is 24% below its 52-week high (Feb 10), but the business held up: revenue +11.0%, earnings per share +13.1%, free cash flow +77.2%.
Some numbers held up (revenue +11.0%, earnings per share +13.1%, free cash flow +77.2%), others slipped. The price is 24% below its 52-week high.
The price is 24% below its 52-week high, and the business changed too.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 9 numbers, high vs now
- Revenue, last 12 months$81M → $89M (+11.0%)held up
- Revenue growth rate+12.9% → +11.0% a year (−1.9 pts)about the same
- Earnings per share, 12 months$1.65 → $1.86 (+13.1%)held up
- Free cash flow, 12 months$15M → $26M (+77.2%)held up
- Operating margin30.9% → 32.3% (+1.4 pts)held up
- Shares outstanding+0.1% (more shares, each owns less)held up
- Stock vs its sector (Health Care)stock −24%, sector median +15% since Feb 10changed
- Price fall vs business numbersprice −24%, revenue/EPS/FCF median +13% (shown, not scored)
- Valuation multipleP/FCF 91.7× at the high → 39.1× now (shown, not scored)
Business numbers as reported at the high (12 months to Sep 30, 2025) vs the latest filing (12 months to Sep 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
At the high ($105.15, Feb 10) the price assumed about 36%/yr free-cash-flow growth; at the low ($76.68, Oct 30) about 19%; today about 19%. The last 3 years delivered 23%/yr (free cash flow).
Dashed line: what the last 3 years delivered, 23%/yr (free cash flow)
| High | Low | Now | |
|---|---|---|---|
| Price | $105.15Feb 10 | $76.68Oct 30 | $79.42 |
| Implied growth | +36% | +19% | +19% |
| P/E | 63.8× | 41.2× | 42.6× |
| P/FCF | 91.7× | 37.8× | 39.1× |
What this means: the higher the implied growth, the more the price already counts on. If today's number sits well below what the business has delivered, the market expects less than its track record.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 15.0% ±2 points. Bear = 10.5% and 13.0%; bull = 8.5% and 17.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price sits inside the range.
What the price implies To be worth today’s price, IRMD’s free cash flow would need to grow about 19% a year for five years; our estimate uses 15%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much IRMD moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves much less than the market, but its own price swings are 2.5× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.62
- Volatility
- 32% vs 13% SPY
- Correlation SPY
- 0.25
- Correlation QQQ
- 0.19
How it ranks
Where IRMD stands vs every one of the 2,467 stocks we cover that has the number. Longer bar = better.
Top quarter on 1 of 5 measures
- Discount to fair value estimate21% · price above our base caseLowest 33%of 1,507
- Free cash flow yield2.6% · free cash flow vs market capLowest 35%of 1,690
- Dividends + buybacks yield1.6% · cash paid out or used to retire shares, vs market capLowest 39%of 2,227
- Revenue growth, last 12 months+11% · vs the 12 months beforeTop 45%of 2,184
- Operating margin32% · of sales kept as operating profitTop 9%of 1,549
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
DCF $62.63 · FCF value $39.71
Assumes 15.0% growth for 5 years (revenue grew 16.3% a year FY22–FY25; capped at 15%), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $2.03 a share (trailing 12 months to Sep 30, 2026), from the 10-Q filed Oct 30, 2026.
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
Cash returnsFree cash flow grew 77% over the last 12 months vs the 12 months before.
GrowthSales compounded 16% a year from FY2022 to FY2025.
ProfitabilityOperating margin of 32% over the last 12 months.
ProfitabilityReturn on equity of 23% over the last 12 months.
GrowthDiluted EPS grew 17% to $1.75 in FY2025.
Top bearish points 3 of 5
ValuationOur DCF fair value estimate is $62.63, 21% below the price.
ValuationP/E of 42.6× vs a 28.9× median for the 161 Health Care companies we cover.
ValuationPrice / book of 9.6×, above the 4.8× median for the 291 Health Care companies we cover.
All fundamentals
P/E 42.6 · FCF yield 2.6% · ROE 23%
Valuation
- P/E
- 42.6×Health Care median 28.9×
- Price / FCF
- 39.1×
- FCF yield
- 2.6%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 11.45×
- Price / book
- 9.61×
- Market cap
- $1.0Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $89M
- Sales growth, 12 months
- +11.0%vs the 12 months before
- Sales growth, 3 yrs
- +16.3%/yrfrom FY2022
- Diluted EPS, 12 months
- $1.87
- EPS growth, last FY
- +16.7%
- Net income, 12 months
- $24M
- Net income growth
- +13%12 months vs before
Profitability
- Gross margin
- 75.5%
- Operating margin
- 32.3%
- Net margin
- 26.8%
- FCF margin
- 29.3%
- Return on equity
- 23%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $63M
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- n/ainterest expense not tagged in SEC data
Cash flow & returns
- Free cash flow, 12 months
- $26M
- FCF growth, 12 months
- +77%
- Dividend yield
- 1.59%$16M paid
- Payout ratio
- 68%
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +0.1%diluted shares vs a year ago
- Stock-based comp
- $3M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From iRadimed’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +14%
- Free cash flow, 12 months$0.0B
- Free-cash-flow yield2.6%
- Free-cash-flow margin20%
- Gross margin76%
- Operating margin34%
- Return on invested capital55%
- Return on equity23%
- Sales growth (latest quarter vs year-ago quarter)+14%
- Net debt / EBITDA−2.1×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $79.42
- Fair value est.base case$62.63−21.1%
- 52-wk lowlowest close, 1 year$76.68−3.5%
- PriceMon Nov 2 close$79.42you are here
- 52-wk highhighest close, 1 year$105.15+32.4%
Momentum & 52-week range
RSI 35 · 5 days −6.2%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
IRMD is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on iRadimed in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.